曲妥珠单抗治疗HER2^＋乳腺癌的临床进展  

Clinical progress in treatment of HER2 positive breast cancer with trastuzumab

作　　者：朱燕(综述)[1] 赵玉亮(审校)[1] 

机构地区：[1]北京大学第一医院肿瘤化疗科,100009

出　　处：《国际肿瘤学杂志》2010年第8期593-596,共4页Journal of International Oncology

摘　　要：临床研究显示曲妥珠单抗与化疗联合用于人表皮生长因子受体2（HER2）^＋转移性乳腺癌的治疗以及早期乳腺癌的新辅助和辅助治疗，能显著延长患者的生存时间。其与内分泌治疗联合治疗HER2^＋且雌激素受体阳性的转移性乳腺癌，疗效优于单纯内分泌治疗。曲妥珠单抗联合其他靶向治疗药物，能够逆转肿瘤对曲妥珠单抗的耐药。疾病进展后继续应用曲妥珠单抗仍可使患者生存受益。Clinical studies have shown that trastuzumab combined with chemotherapy can significantly improve survival in treatment of HER2-positive metastatic breast cancer as well as in the neoadjuvant and adjuvant therapy for HER2-positive early breast cancer. In patients with HER2-positive and hormone receptor-positive metastatic breast cancer, adding trastuzumab to endocrine therapy improves treatment efficacy. Resistance to trastuzumab may be reversed by incorporating other targeted therapeutic drugs. Patients can still benefit from continuing trastuzumab after their disease progresses.

关 键 词：乳腺肿瘤 受体 表皮生长因子 

分 类 号：R979.1[医药卫生—药品]